Christopher Joseph Cates

Christopher Joseph Cates

Auto-generated profile, based on publicly available information

Christopher Joseph Cates

St George's, University of London; Population Health Research Institute; Cranmer Terrace London UK SW17 0RE

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2019 in BMJ
Verified
Journal Article
Open access
PDF file
JSJonathan A C Sterne
Jonathan A C Sterne
JSJelena Savović
Jelena Savović
MPMatthew J Page
Matthew J Page
RERoy G Elbers
Roy G Elbers
NBNatalie S Blencowe
Natalie S Blencowe
JHJulian P T Higgins
Julian P T Higgins
Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for randomised trials is the Cochrane risk-of-bias tool. We updated the tool to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.

11 October 2010 in Thorax
Verified
Journal Article
Closed access
PDF file
HPHelen Petsky
Helen Petsky
CCC J Cates
C J Cates
TLT J Lasserson
T J Lasserson
ALA M Li
A M Li
CTC Turner
C Turner
Anne B. ChangAnne B. Chang
Anne B. Chang
Asthma severity and control can be measured both subjectively and objectively. Traditionally asthma treatments have been individualised using symptoms and spirometry/peak flow. Increasingly treatment tailored in accordance with inflammatory markers (sputum eosinophil counts or fractional exhaled nitric oxide (FeNO) data) is advocated as an alternative strategy. The objective of this review was to evaluate the efficacy of tailoring asthma interventions based on inflammatory markers (sputum analysis and FeNO) in comparison with clinical symptoms (with or without spirometry/peak flow) for asthma-related outcomes in children and adults. Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and reference lists of articles were searched. The last searches were in February 2009. All randomised controlled comparisons of adjustment of asthma treatment based on sputum analysis or FeNO compared with traditional methods (primarily clinical symptoms and spirometry/peak flow) were selected. Results of searches were reviewed against predetermined criteria for inclusion. Relevant studies were selected, assessed and data extracted independently by at least two people. The trial authors were contacted for further information. Data were analysed as ‘intervention received’ and sensitivity analyses performed. Six (2 adults and 4 children/adolescent) studies utilising FeNO and three adult studies utilising sputum eosinophils were included. These studies had a degree of clinical heterogeneity including definition of asthma exacerbations, duration of study and variations in cut-off levels for percentage of sputum eosinophils and FeNO to alter management in each study. Adults who had treatment adjusted according to sputum eosinophils had a reduced number of exacerbations compared with the control group (52 vs 77 patients with ≥1 exacerbation in the study period; p=0.0006). There was no significant difference in exacerbations between groups for FeNO compared with controls. The daily dose of inhaled corticosteroids at the end of the study was decreased in adults whose treatment was based on FeNO in comparison with the control group (mean difference −450.03 μg, 95% CI −676.73 to −223.34; p<0.0001). However, children who had treatment adjusted according to FeNO had an increase in their mean daily dose of inhaled corticosteroids (mean difference 140.18 μg, 95% CI 28.94 to 251.42; p=0.014). It was concluded that tailoring of asthma treatment based on sputum eosinophils is effective in decreasing asthma exacerbations. However, tailoring of asthma treatment based on FeNO levels has not been shown to be effective in improving asthma outcomes in children and adults. At present, there is insufficient justification to advocate the routine use of either sputum analysis (due to technical expertise required) or FeNO in everyday clinical practice.

1 January 2001 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
DBD. Brocklebank
D. Brocklebank
FRF. Ram
F. Ram
JWJ. Wright
J. Wright
PBP. Barry
P. Barry
CCC. Cates
C. Cates
JWJ. White
J. White
Health Technology Assessment Volume: 5, Issue: 26, Published in October 2001

25 August 2017 in Research Synthesis Methods
Verified
Journal Article
Closed access
PDF file
GRGerta Rucker
Gerta Rucker
CCChristopher J. Cates
Christopher J. Cates
GSGuido Schwarzer
Guido Schwarzer

19 July 2006
Verified
Reference Entry
Closed access
PDF file
TGT L Giles
T L Giles
TLT J Lasserson
T J Lasserson
BSB H Smith
B H Smith
JWJ White
J White
JWJ Wright
J Wright
CCC J Cates
C J Cates

25 January 2006 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PPPhillippa Poole
Phillippa Poole
ECEmme E Chacko
Emme E Chacko
RWRichard Wood-Baker
Richard Wood-Baker
CCChristopher J Cates
Christopher J Cates